Norway’s Pre Diagnostics Has Alzheimer’s Test In Its Sights
Pre Diagnostics AS is a 2.5-year-old Oslo company developing a blood-based test performed by a GP and sent to a lab for early Alzheimer’s diagnosis.
You may also be interested in...
Norway’s Pre Diagnostics uses the intracellular approach to neurodegenerative disease diagnosis. It believes its technology will open up a world of precision medicine for Alzheimer’s disease patients.
The operating environment for medical technology companies becomes more complex, competitive and costly every year. There is no expectation that 2022 will buck that trend, even as the medtech sector prepares for a third year of working under conditions shaped by the COVID-19 pandemic.
Boston Consulting Group began writing the third iteration of its report on next-generation commercial models to meet evolving medtech customer needs before COVID struck. But it findings and recommendations were even more relevant once the report – dubbed Milkman 3.0 ̶ was finally released in spring 2021, when learnings from the pandemic were being factored in by the medtech industry.